Affiliation:
1. Zuckerberg San Francisco General Hospital and Trauma Center and University of California San Francisco
Funder
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Subject
Immunology,Rheumatology,Immunology and Allergy
Reference13 articles.
1. BrillA IppolitoB.The economics of biologic drugs: a further response to Bach et al.2019. URL:https://www.healthaffairs.org/do/10.1377/hblog20190807.554429/full/.
2. Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States
3. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars
4. WoolettG JacksonJ.Use of step through policies for competitive biologics among commercial US insurers.2018. URL:https://avalere.com/insights/use-of-step-through-policies-for-competitive-biologics-among-commercial-us-insurers.
5. How logically impossible patents block biosimilars
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献